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OBJECTIVES To evaluate the long-term functional and hemodynamic effects of right ventricular outflow
tract (RVOT) pacing by comparison with right ventricular apical (RVA) pacing.
BACKGROUND Acute studies have suggested that RVOT pacing could significantly improve cardiac
performance in comparison with RVA pacing but no data are available in chronically
implanted patients.
METHODS Sixteen patients with chronic atrial tachyarrhythmia and complete AV block were included.
Left ventricular ejection fraction (LVEF) was .240% in ten and ,40% in six. Patients were
implanted with a standard DDDR pacemaker connected to two ventricular leads. A screw-in
lead was placed at the RVOT and connected to the atrial port. A second lead was positioned
at the RVA and connected to the ventricular port. Right ventricular outflow tract and RVA
pacing was achieved by programming either the AAIR or the VVIR mode respectively. Four
months later patients were randomized so as to undergo either RVOT or RVA pacing for
three months according to a blind crossover protocol. Apart from the pacing mode,
programming remained unchanged throughout the study. At the end of each period, NYHA
class, LVEF, exercise time and maximal oxygen uptake were assessed.
RESULTS No significant difference was observed between the two modes for all the parameters analyzed.
These identical results were observed in all patients globally, in patients with LVEF .240%
as in those with LVEF ,40%.
CONCLUSIONS Within the limits of this study, no symptomatic improvement or hemodynamic benefit was
noted after three months of RVOT pacing, by comparison with RVA pacing. (J Am Coll
Cardiol 1999;33:311–6) © 1999 by the American College of Cardiology
One of the main objectives of modern cardiac pacing is to
optimize, or at least to stabilize, cardiac performance which
is dependent on three main parameters: chronotropic func-
tion, quality of AV synchrony when applicable and ventric-
ular activation sequence in relation to the site selected for
implanting the ventricular lead. For 35 years, the right
ventricular apex (RVA) has been the elective pacing site (1).
Experimental (2,3) and clinical studies (4,5), however,
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suggest that this site is not optimal in terms of cardiac function.
Other sites have recently been proposed for right ventricular
implantation: right ventricular outflow tract (RVOT), either
septal (6) or in the right ventricular free wall (7,8), and the
His-bundle area (9,10). Among these alternative sites, only
RVOT was evaluated for feasibility and safety using chronically
implanted screw-in leads (11).
Results of acute hemodynamic studies, although controver-
sial (12), have shown increased cardiac output as a result of
RVOT pacing, relatively to RVA pacing (7,8). Some authors
therefore have hypothesized that RVOT could become the
elective site for ventricular pacing (13), subject to obtaining
positive results from chronic comparative assessments.
The aim of this study was to evaluate the long-term
effects of RVOT pacing and of RVA pacing on symptoms,
exercise tolerance and left ventricular function in an intra-
patient comparison.
PATIENTS AND METHODS
The inclusion criteria were: first, the existence of a chronic
atrial tachyarrhythmia, to rule out any potential hemody-
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namic influence of the atrial systole and any further need to
optimize AV delay in case of dual chamber pacing. Second,
the existence of a complete AV block, either spontaneous or
induced by radiofrequency ablation of the AV junction, to
ensure permanent and complete ventricular capture during
pacing. Third, the possibility for each patient to perform an
exercise test. All patients gave their informed consent and
the study protocol was approved by the local ethics com-
mittee.
Pacing configuration. Two ventricular leads were im-
planted in each patient. A passive lead (any commercially
available lead could be used) was conventionally placed at
the RVA. A screw-in lead (any commercially available
screw-in lead could be used) was implanted at the RVOT
free wall, as shown in Figure 1. The positions of the leads
were controlled by fluoroscopy and surface ECG confirmed
QRS axis normalization (0 to 90°) during RVOT pacing.
The two ventricular leads were connected to a conventional
DDDR pacemaker (Medtronic Elite or Thera DR,
Medtronic Inc, Minneapolis, Minnesota). The RVA lead
was connected to the ventricular port and the RVOT lead to
the atrial port. Single site right ventricular apical program-
ming thus provided single site VVIR pacing at the apex and
AAIR programming ensured single site VVIR pacing at the
RVOT. DDDR programming with the shortest program-
mable AV delay value (30 ms) provided dual site right
ventricular and almost simultaneous pacing. The lower and
upper rate limits were individually programmed depending
on the estimated needs in each patient. The lower rate limit
was set between 60 and 75 bpm and the upper rate limit
from 120 to 140 bpm. However, the programmed values of
lower and upper rate limits remained unchanged all along
the study. The activity response curve (sensor) was pro-
grammed and set at “7” in all patients. Finally the sensitivity
on the atrial channel (connected to the RVOT lead) was set
at a low value (2 mV) in order to prevent the potential risk
of cross-talk and of pacemaker mediated tachycardia, during
the “wash-in” period with the pacemaker programmed in
the DDDR mode with a short AV delay.
Study design. Because all patients presented with chronic
atrial tachyarrhythmia at inclusion and because ventricular
rate control was achieved by AV junction ablation, the
crossover study only started four months later to rule out any
hemodynamic improvement that could potentially be due to
the regression of a tachycardia-induced cardiomyopathy.
During the first four months, the pacemaker was pro-
grammed in the DDDR mode. This “wash-in” period was
used to clear any carry-on effect of the pacing site during the
crossover study. The crossover study included two periods of
three months each, randomized as single site VVIR-RVA
or single site VVIR-RVOT mode. Throughout the cross-
over study, the pacing parameters remained unchanged,
resting and maximal heart rate and sensor programming in
particular. Patients were their own control. The physicians
performing the different tests were unwise to the current
programming or to the results of the preceding assessment.
Pharmacological treatment remained unchanged through-
Abbreviations and Acronyms
AV 5 atrioventricular
CO 5 cardiac output
LVEF 5 left ventricular ejection fraction
NYHA 5 New York Heart Association
RVA 5 right ventricular apex
RVOT 5 right ventricular outflow tract
VVIR-RVA pacing 5 single site right ventricular apical
pacing
VVIR-RVOT pacing 5 single site right ventricular
outflow tract pacing
Figure 1. Chest X ray, (A) frontal and (B) sagittal projections
showing the position of the two ventricular leads: the passive lead
at the right ventricular apex and the screw-in lead at the RVOT
free wall.
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out the study, especially ACE inhibitors in patients with
LVEF ,40%. Antiarrhythmic therapy by amiodarone was
continued in only one patient because of nonsustained
ventricular tachycardia.
Analyzed parameters. At the end of each three months
period spent, either in VVIR-RVA or VVIR-RVOT mode,
the pacing system was verified as working well before
evaluation. Lead impedence and pacing threshold were
measured via telemetry on the two ventricular leads. Per-
manent ventricular pacing (100% paced cycles) was con-
firmed by pacemaker data (rate histogram) interrogation.
Symptoms were evaluated by history according to the
NYHA classification. QRS axis and duration were mea-
sured from a standard 12 leads surface ECG recording.
Cardiac output (CO) was determined by Doppler ultra-
sonography (Hewlett Packard, Sonos 1000, Boston, Mas-
sachusetts, 2.5 MHz probes) (14). Left ventricular ejection
fraction (LVEF) was measured at rest by radionuclide
angiography (Sopha medical, DSX rectangular camera).
Cardiac output and LVEF were measured at rest and at the
same heart rate for each evaluation. Exercise test with
oxygen consumption measurement (Eos Sprint Jaeger and
Oxycon) was carried out for study requirements according to
the same standardized protocol within symptom limitations,
using the same equipment and under similar conditions for
each evaluation. After the “wash-in” period, a run-in test in
the DDDR mode was designed to familiarize the patients
with the equipment and the whole procedure. Measuring
oxygen consumption ensured that the test was actually
maximal. Continuous ECG recording controlled that pac-
ing was permanent with a full ventricular capture.
Statistical analysis used a nonparametric comparison.
Results are expressed as mean 6 standard deviation. A
Kruskall and Wallis analysis of variance was performed to
compare the distribution of either treatment group. When
significant differences were found, a Wilcoxon signed rank
test compared each pacing configuration. Each patient
being their own control, a value of p , 0.05 was considered
significant. Finally a Spearman rank test evaluated the
correlation between the different results according to the
treatment regimen.
RESULTS
Patients. Sixteen patients aged 53 to 80 (mean age 69 6
7.5 years) were included in the study. Baseline clinical
characteristics are reported in Table 1. At the end of the
“wash-in” period in DDDR mode (before starting the
crossover study) ten patients were in New York Heart
Association (NYHA) class I, three in class II and three in
class III. The mean LVEF was $40% in ten patients and
,40% in six. Patients with LVEF ,40% were significantly
older and their cardiac output was significantly lower than in
patients with LVEF $40%. Atrial fibrillation was present in
15 patients and atrial flutter was found in only one. Intrinsic
ventricular conduction, as documented on the last ECG
recorded before implantation, could be considered as nor-
mal in 12 patients (QRS duration #120 ms). Four patients
had a right bundle branch block. No left bundle branch
block was observed.
Implantation procedure and pacing system. Atrioventric-
ular junction ablation was performed in 15 patients. One
patient had spontaneous complete heart block and was
already implanted with a standard VVIR pacemaker. The
additional RVOT lead was implanted at the time of elective
pacemaker replacement. No complication linked to the
pacing system was noted at implantation and throughout a
mean follow-up duration of 10.4 6 3.6 months. In partic-
ular, there was no dislodgement of RVOT leads. Chronic
pacing thresholds did not differ significantly between RVA
and RVOT leads (1.19 6 1.00 V vs. 1.33 6 1.01 V, pulse
width 0.5 ms).
Analyzed parameters. No significant difference between
dual site right ventricular pacing and single site RVOT
pacing was observed for the mean QRS axis (69.3 6 38.5°
vs. 85.3 6 8.3°, p 5 NS) and for the paced QRS duration
(163.3 6 21.9 ms vs. 164.0 6 18.8 ms, p 5 NS). However,
the paced QRS morphology was clearly different in the two
pacing modes, reflecting modifications in the ventricular
Table 1. Patients’ Characteristics Before Randomization
All Patients
(n 5 16)
LVEF >40%
(n 5 10)
LVEF <40%
(n 5 6)
Age (years) 69.7 6 7.5 66.7 6 7.8 74.7 6 3.6*
Male/Female 14/2 8/2 6/0
Associated heart disease n 5 7 MVR (n 5 1) IHD (n 5 2)
DCM (n 5 3)
MR (n 5 1)
LVEF (%) 42 6 13 51 6 5 27 6 9**
CO (l/mn) 4.6 6 1.9 5.3 6 1.9 3.4 6 0.8*
A fibrillation/A flutter 15/1 10/0 5/1
* 5 p , 0.05; ** 5 p , 0.01. Comparisons are made between patients with LVEF $40% and LVEF ,40%.
LVEF 5 left ventricular ejection fraction; CO 5 cardiac output; A 5 atrial; MVR 5 mitral valve replacement; IHD 5
ischemic heart disease; DCM 5 dilated cardiomyopathy; MR 5 mitral regurgitation.
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activation sequence. Arguments concordant with a pseu-
dofusion phenomenon due to very short (,30 ms) sponta-
neous conduction time from the outflow tract to the apex
and resulting in effective RVOT pacing only were never
observed during dual site right ventricular pacing. As could
be expected, the QRS axis was significantly different during
RVA pacing (268.0 6 16.1°, p , 0.00001). Although it
was slightly longer during RVA pacing (172.0 6 22.7 ms,
p 5 NS), the paced QRS duration did not significantly
differ.
With regard to symptoms, each patient retained their
initial NYHA functional status in both pacing configura-
tions.
Global results concerning the effects of RVA and RVOT
pacing on LVEF, CO, exercise time and peak oxygen
consumption are shown in Table 2. Individual changes for
LVEF and CO are shown in Figures 2 and 3, respectively.
Considering the patient population as a whole, no signifi-
cant differences in the various parameters were noted
between the two pacing configurations. Subgroup analysis
produced the same results in the ten patients whose cardiac
function was normal or slightly impaired, as defined by an
LVEF $40% before the crossover study. In the patients
whose LVEF was ,40% before the crossover study, there
was no difference either in LVEF, CO, exercise time and
peak oxygen consumption, regardless of the pacing site,
either RVA or RVOT.
DISCUSSION
This study did not elicit any difference between chronic
RVA pacing and RVOT pacing in terms of NYHA
classification, LVEF, cardiac output, exercise time and peak
oxygen consumption. Nonetheless, the effectiveness and
safety of RVOT pacing at ten months were confirmed.
Hemodynamic effects of RVA pacing. The right ventric-
ular apex remains the elective site for implanting permanent
ventricular leads. However, by modifying the normal acti-
vation and contraction sequence, RVA pacing has been
demonstrated to alter both systolic and diastolic cardiac
function. In patients with normal intrinsic conduction and
without structural heart disease, the effects of pacing on
cardiac performance have been assessed by Rosenqvist et al.
(4) and Leclercq et al. (5). In these studies atrial pacing
produced a significant improvement in systolic left ventric-
ular function as compared with atrioventricular pacing at the
optimal AV delay in each patient. This benefit was observed
for global and regional LVEF by radionuclide angiography
(4,5), and for hemodynamics both at rest and during
exercise (5). The effects on diastolic function were studied
by Bedotto et al. (15) who showed significant alteration
during RVA pacing in patients with low LVEF.
In patients with severe left ventricular systolic dysfunction
and without conventional indication for pacing, permanent
short-AV delay DDD pacing with the ventricular lead
placed at the right ventricular apex was proposed as an
adjunctive treatment for advanced heart failure (16,17). The
clinical value of this new therapeutic approach was not
confirmed in a controlled study (6). There is, however, a
strong presumption of short and long term efficacy in some
subgroups of patients, in particular in patients with long PR
interval in spontaneous sinus rhythm (18). The results of the
acute hemodynamic study by Nishimura et al. (18) clearly
show that a positive response from short AV delay DDD
pacing resulted from optimization in left ventricular filling
by correction for mechanical AV dyssynchrony in the left
heart. At that time the general view was that the potential
detrimental effects of ventricular pacing at the right ventric-
ular apex on the left ventricular function were largely
counterbalanced by the benefits of extended filling time (17)
in that particular subgroup of responder patients. Further
studies assessed the potential interest of improving both theFigure 2. Individual patient evolution for LVEF.
Table 2. Results for the Principal Analyzed Parameters
RVA RVOT
All
Patients
(n 5 16)
LVEF
>40%
(n 5 10)
LVEF
<40%
(n 5 6)
All
Patients
(n 5 16)
LVEF
>40%
(n 5 10)
LVEF
<40%
(n 5 6)
LVEF (%) 40 6 12 48 6 7 30 6 10 42 6 12 48 6 5 28 6 9
CO (l/mn) 4.5 6 2.1 5.2 6 2.3 3.4 6 0.9 4.4 6 1.8 5.0 6 1.9 3.4 6 0.9
ED (mn) 12.2 6 4.4 13.6 6 3.8 9.4 6 4.5 12.6 6 4.8 14.6 6 4.3 9.7 6 4.2
VO2 max
(ml/mn/kg)
16.2 6 3.8 17.2 6 4.1 14.3 6 2.6 16.2 6 4.7 17.9 6 5.0 13.6 6 3.1
RVA 5 right ventricular apex pacing; RVOT 5 right ventricular outflow tract pacing; LVEF 5 left ventricular ejection fraction; CO 5 cardiac output; ED 5 exercise duration;
VO2 max 5 peak of oxygen consumption.
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AV synchrony and the activation of the paced ventricle. A
first attempt in this way consisted in pacing the right
ventricle at alternative sites, especially the RVOT or the
septal wall. Multisite biventricular pacing (19,20) and single
site left ventricular pacing (21) were recently introduced and
provided encouraging results during acute studies with
temporary pacing. These new pacing techniques are now
under evaluation.
Technical aspects: feasibility and safety of RVOT lead
implantations. Right ventricular outflow tract implanta-
tions were previously evaluated by Barin et al. in a random-
ized study (11). The implantation time was the same for
RVA or RVOT leads. Pacing thresholds at one month did
not differ between RVA and RVOT implantations. No lead
dysfunction was noted although one lead was dislodged in
the RVOT group, in a patient who presented with a
“pacemaker twiddler” syndrome. In that series, as in the
present series, no difference in chronic thresholds was found
between RVA and RVOT after a mean follow up of 73
months. Taking Barin’s experience into account, we used
screw-in leads and all implantations were successful. How-
ever, because the mechanical stresses imposed on the leads
in RVOT position may be greater, a longer follow-up
period will provide a better assessment of the very long-term
reliability of that configuration. This also may limit the
choice of other right ventricular alternative sites, for exam-
ple His area pacing, in terms of safety for the patients.
QRS axis and duration. Although it was slightly greater
during RVA pacing than during RVOT pacing, QRS
duration was not significantly different between the two
configurations. Only the QRS axis was different between
the two pacing modes. These findings are consistent with
those reported by Giudici et al. (7) where RVOT pacing
was sited on the free wall of the RVOT. In the series of
Gold et al. (6) RVOT pacing was sited on the septal wall of
the RVOT and the mean paced QRS duration was 151 6
44 msec. In that study, although RVOT pacing was not
compared with RVA pacing, it was suggested that the exact
position of RVOT leads influences the QRS duration. In
the studies of Buckingham et al. (12), the QRS duration was
identical in RVA and RVOT pacing. Only dual site
synchronous pacing (i.e., simultaneous RVA and RVOT
pacing), provided thinner QRS complexes (12).
Left ventricular ejection fraction. At the end of each
crossover period no difference was found between RVA or
RVOT pacing. At inclusion all patients presented with
chronic atrial tachyarrhythmia. There was therefore the
possibility that a “tachycardia induced cardiomyopathy”
could alter cardiac performance. The “wash-in” period of
dual site RVA and RVOT synchronous pacing which
preceded the crossover study was thus designed to permit
potential restoration of cardiac systolic function (22). In
addition, if a left ventricular systolic dysfunction induced by
tachycardia had persisted beyond the three months of
synchronous pacing, the latest configuration studied (RVA
or RVOT) would have been systematically favored. This
hypothesis is unlikely because: first, there was no difference
in LVEF between simultaneous stimulation, RVA and
RVOT; second, the crossover was randomized and ten
patients were first studied in RVA and six in RVOT. Last,
the first crossover evaluations started four months after the
time of ablation which appears sufficient to correct a systolic
dysfunction potentially induced by tachycardia (22).
Cardiac output. No difference was observed according to
the pacing configuration in the population studied overall.
The baseline LVEF did not influence that parameter in
subgroup analysis. Four acute studies explored cardiac out-
put during RVOT pacing with controversial results. In the
series of Giudici et al. (7), RVOT pacing at the free wall was
significantly better than RVA pacing in terms of cardiac
output. That study was not randomized and it is not
specified whether the physician who performed the tests was
aware of the pacing mode. In any case, that study consti-
tuted the most comprehensive experiment in that field,
involving 89 patients. De Cock et al. in a randomized blind
acute study observed higher cardiac indexes during RVOT
pacing than in RVA pacing at 85, 100 and 120 bpm in
patients without structural heart disease (8). In contrast, in
five out of eight patients with LVEF #50% or significant
coronary artery disease, RVOT pacing at 120 bpm de-
creased cardiac index. Gold et al. compared cardiac output
during RVOT DDD septal pacing in relation to intrinsic
heart rate in patients whose LVEF was ,30% (6). The
randomized study design partially made up for the restricted
number of patients. In addition, the tests were carried out
without knowing the pacing mode used. In that study, no
difference was noted between RVOT pacing and intrinsic
heart rate. Buckingham’s study (12), which assessed cardiac
output under RVA, RVOT and dual site (RVA 1 RVOT)
pacing modes only elicited a trend in favor of simultaneous
dual site right ventricular pacing.
All these studies were conducted acutely and mainly
differed from ours because all patients had normal sinus
rhythm or were placed in the atrium. Evaluation was
conducted during ventricular asynchronous pacing (7,8), or
during atrioventricular synchronous pacing with fixed (12)
or variable AV delay (i.e., 100 ms to 175 ms) (6). Cowell et
al. (23) noted the need for a shorter AV delay for septal
Figure 3. Individual patient evolution for cardiac output.
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right ventricular DDD pacing to be optimal as compared
with apical right ventricular DDD pacing. With this opti-
mized programming, septal short AV delay VDD pacing
provided higher cardiac output as compared with spontane-
ous rhythm and RVA VDD pacing.
In our study, all patients presented with chronic atrial
tachyarrhythmia which rules out any potential influence of
the atrial systole on cardiac output and the necessity for
atrioventricular optimization depending on the ventricular
pacing site. Our observations therefore only apply to a
purely ventricular output and should be limited to these
particular patients. Nonetheless, in the present series,
changing the QRS axis implicating inverted ventricular
contraction sequences without modification of the QRS
width did not modify cardiac performance at rest and during
exercise.
Limitations of the study. These results are to be interpreted
in consideration of the small population of patients although,
under the methods used, each patient was his or her own
control. The pacing mode selection was randomized and the
tests were conducted without knowing the programmed mode
and in awareness of the results from the previous evaluation
(RVA or RVOT). This small number of patients was, how-
ever, considered as relevant on the basis of a Spearman rank
correlation test (r9 ranging from 0.75 to 0.91).
Conclusions. This study confirmed the reliability and
safety of chronic RVOT pacing with screw-in leads, but no
significant improvement in symptoms and exercise tolerance
or hemodynamic benefit was noted after three months of
permanent RVOT pacing, compared with RVA pacing in
patients with chronic atrial tachyarrhythmia and complete
heart block. The study did not bring about any fact to
encourage changing the usual pacing site on the right
ventricle. Finding alternative ventricular pacing sites or
other configurations to optimize cardiac performance may
therefore require further investigations.
Reprint requests and correspondence: Dr. Claude Daubert,
De´partement de Cardiologie & Maladies Vasculaires, Centre
Cardio-Pneumologique, Pontchaillou CHRU, 2, rue Henri le
Guilloux, 35033 Rennes Cedex 09, France.
REFERENCES
1. Furman S, Schwedel JB. An intracardiac pacemaker for
Stokes-Adams seizure. N Eng J Med 1959;261:943–8.
2. Tyers GFO. Optimal electrode implantation site for asyn-
chronous bipolar cardiac pacing. Ann Surg 1968;167:168–79.
3. Grover M, Glantz SA. Endocardial pacing site affects left
ventricular end-diastolic volume and performance in the intact
anesthetized dog. Circ Res 1983;53:72–85.
4. Rosenqvist M, Isaaz K, Botvinick EH, et al. Relative importance
of activation sequence compared to atrioventricular synchrony in
left ventricular function. Am J Cardiol 1991;67:148–56.
5. Leclercq C, Gras D, Le Helloco A, Nicol L, Mabo P, Daubert
C. Hemodynamic importance of preserving the normal se-
quence of ventricular activation in permanent cardiac pacing.
Am Heart J 1995;129:1133–41.
6. Gold MR, Shorofsky SR, Metcalf MD, Feliciano Z, Fisher
ML, Gottlieb SS. The acute hemodynamic effects of right
ventricular septal pacing in patients with congestive heart
failure secondary to ischemic or idiopathic dilated cardiomy-
opathy. Am J Cardiol 1997;79:679–81.
7. Giudici M, Thornburg GA, Buck DL, et al. Comparison of
right ventricular outflow tract and apical lead permanent
pacing on cardiac output. Am J Cardiol 1997;79:209–12.
8. De Cock CC, Meyer A, Kamp O, Visser CA. Hemodynamic
benefits of right ventricular outflow tract pacing: Comparison
with right ventricular apex pacing. PACE 1998;21:536–41.
9. Mabo P, Scherlag BJ, Munsif A, Otomo K, Lazzara R. A
technique for stable His-bundle recording and pacing: elec-
trophysiological and hemodynamic correlates. PACE 1995;
18:1894–901.
10. Karpawich PP, Justice CD, Chang CH, Gause CY, Kuhns
LR. Septal ventricular pacing in the immature canine heart: a
new perspective. Am Heart J 1991;121:827–33.
11. Barin ES, Jones SM, Ward DE, Camm AJ, Nathan AW. The
right ventricular outflow tract as an alternative permanent
pacing site: long-term follow-up. PACE 1991;14:3–6.
12. Buckingham TA, Candinas R, Schlapfer J, et al. Acute
hemodynamic effects of atrioventricular pacing at differing
sites in the right ventricle individually and simultaneously.
Pace 1997;20:909–15.
13. Sutton R. Right ventricular outflow tract pacing. Eur J C P E
1996;6:6–7.
14. Ilhen H, Amlie JP, Dale J, et al. Determination of cardiac output
by Doppler echocardiography. Br Heart 1984;51:54–60.
15. Brignole M, Gianfranchi L, Meozzi C, et al. Influence of
atrioventricular junction radiofrequency ablation in patients
with chronic atrial fibrillation and flutter on quality of life and
cardiac performance. Am J Cardiol 1994;74:242–6.
16. Cowell R, Morris-Thurgood J, Ilsley C, Paul V. Septal short
atrioventricular delay pacing: additional hemodynamic im-
provements in heart failure. Pacing Clin Electrophysiol 1994;
17:1980–3.
17. Bedotto JB, Grayburn PA, Black WH, et al. Alterations in left
ventricular relaxation during atrioventricular pacing in hu-
mans. J Am Coll Cardiol 1990;15:658–64.
18. Hochleitner M, Hortnagl H, Choi-Keung Ng, Hortnagl M,
Gschnittzer F, Zechmann W. Usefulness of physiologic dual-
chamber pacing in drug resistant idiopathic dilated cardiomy-
opathy. Am J Cardiol 1990;66:198–202.
19. Brecker SJ, Xiao HB, Sparrow J, Gibson DJ. Effects of
dual-chamber pacing with short atrioventricular delay in
dilated cardiomyopathy. Lancet 1992;340:1308–11.
20. Nishimura RA, Hayes DL, Holmes DR Jr, Tajik AJ. Mech-
anism of hemodynamic improvement by dual-chamber pacing
for severe left ventricular dysfunction: an acute Doppler and
catheterization study. J Am Coll Cardiol 1995;25:281–8.
21. Cazeau S, Ritter P, Lazarus A, et al. Four-chamber pacing in
dilated cardiomyopathy. PACE 1996;19:1748–57.
22. Leclercq C, Le Breton H, Pavin D, Victor F, Mabo P,
Daubert C. Acute hemodynamic response to biventricular
pacing in patients with severe congestive heart failure and
without conventional indication for permanent pacemaker
[abstract]. Circulation 1997;97:I-95.
23. Blanc JJ, Etienne Y, Gilard M, et al. Evaluation of different
ventricular pacing sites in patients with severe heart failure.
Circulation 1997;96:3273–7.
316 Victor et al. JACC Vol. 33, No. 2, 1999
RVOT Chronic Pacing February 1999:311–6
